Associated Papers
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biochimica Et Biophysica Acta. Molecular Cell Research, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
Tyrosine phosphorylation and the inhibitory C-terminal SAM domain moderately affect transient interactions in a EphA2 cytoplasmic fragment in solution: A combined experimental and molecular modeling study.
Shrestha P et al.
Biorxiv : the Preprint Server for Biology, 2025
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biorxiv : the Preprint Server for Biology, 2025
Kinase activity-independent role of EphA2 in the regulation of M-phase progression.
Kaibori Y et al.
Experimental Cell Research, 2020
Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma.
Sheng Y et al.
International Journal of Cancer, 2019
Select a paper to view details